Search research articles
Contact Us
Filters
Showing results (71-80 of 92) with videos related to
Page
of 10
Sort By:
Investigational New Drugs
|
May 4, 2026
Pooled safety analysis of lurbinectedin plus irinotecan in patients with advanced solid tumors
Alejandro Falcón, Gregory M Cote, Javier Molina-Cerrillo, et al.
Nature Communications
|
August 28, 2024
EWS-WT1 fusion isoforms establish oncogenic programs and therapeutic vulnerabilities in desmoplastic small round cell tumors
Gaylor Boulay, Liliane C Broye, Rui Dong, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 11, 2025
Milademetan in advanced solid tumors with MDM2 amplification and wild-type TP53: pre-clinical and phase 2 clinical trial results
Ecaterina E Dumbrava, Thomas E Stinchcombe, Mrinal Gounder, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 13, 2020
Ivosidenib in Isocitrate Dehydrogenase 1<i>-</i>Mutated Advanced Glioma
Ingo K Mellinghoff, Benjamin M Ellingson, Mehdi Touat, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 19, 2023
Phase II Study of Olaparib and Temozolomide for Advanced Uterine Leiomyosarcoma (NCI Protocol 10250)
Matthew Ingham, Jacob B Allred, Li Chen, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
June 3, 2021
Vorasidenib, a Dual Inhibitor of Mutant IDH1/2, in Recurrent or Progressive Glioma; Results of a First-in-Human Phase I Trial
Ingo K Mellinghoff, Marta Penas-Prado, Katherine B Peters, et al.
European Journal of Cancer (Oxford, England : 1990)
|
June 16, 2026
A pooled analysis of phase 2 clinical trials in advanced chordoma
Gregory M Cote, Corrine F Elliott, Astrid Lipplaa, et al.
Nature Medicine
|
June 5, 2023
Camonsertib in DNA damage response-deficient advanced solid tumors: phase 1 trial results
Timothy A Yap, Elisa Fontana, Elizabeth K Lee, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 30, 2021
Results from Phase I Extension Study Assessing Pexidartinib Treatment in Six Cohorts with Solid Tumors including TGCT, and Abnormal CSF1 Transcripts in TGCT
William D Tap, Arun S Singh, Stephen Patrick Anthony, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
January 21, 2026
Camonsertib, an ATRi, in Combination with Low-Dose Gemcitabine in Solid Tumors with DNA Damage Response (DDR) Aberrations: Preclinical and Phase 1b Results
Ezra Y Rosen, Timothy A Yap, Elisa Fontana, et al.
Page
of 10
Search research articles
Search
Showing results (71-80 of 92) with videos related to
Sort By:
Page
of 10
Investigational New Drugs
|
May 4, 2026
Pooled safety analysis of lurbinectedin plus irinotecan in patients with advanced solid tumors
Alejandro Falcón, Gregory M Cote, Javier Molina-Cerrillo, et al.
Nature Communications
|
August 28, 2024
EWS-WT1 fusion isoforms establish oncogenic programs and therapeutic vulnerabilities in desmoplastic small round cell tumors
Gaylor Boulay, Liliane C Broye, Rui Dong, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 11, 2025
Milademetan in advanced solid tumors with MDM2 amplification and wild-type TP53: pre-clinical and phase 2 clinical trial results
Ecaterina E Dumbrava, Thomas E Stinchcombe, Mrinal Gounder, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 13, 2020
Ivosidenib in Isocitrate Dehydrogenase 1<i>-</i>Mutated Advanced Glioma
Ingo K Mellinghoff, Benjamin M Ellingson, Mehdi Touat, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 19, 2023
Phase II Study of Olaparib and Temozolomide for Advanced Uterine Leiomyosarcoma (NCI Protocol 10250)
Matthew Ingham, Jacob B Allred, Li Chen, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
June 3, 2021
Vorasidenib, a Dual Inhibitor of Mutant IDH1/2, in Recurrent or Progressive Glioma; Results of a First-in-Human Phase I Trial
Ingo K Mellinghoff, Marta Penas-Prado, Katherine B Peters, et al.
European Journal of Cancer (Oxford, England : 1990)
|
June 16, 2026
A pooled analysis of phase 2 clinical trials in advanced chordoma
Gregory M Cote, Corrine F Elliott, Astrid Lipplaa, et al.
Nature Medicine
|
June 5, 2023
Camonsertib in DNA damage response-deficient advanced solid tumors: phase 1 trial results
Timothy A Yap, Elisa Fontana, Elizabeth K Lee, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 30, 2021
Results from Phase I Extension Study Assessing Pexidartinib Treatment in Six Cohorts with Solid Tumors including TGCT, and Abnormal CSF1 Transcripts in TGCT
William D Tap, Arun S Singh, Stephen Patrick Anthony, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
January 21, 2026
Camonsertib, an ATRi, in Combination with Low-Dose Gemcitabine in Solid Tumors with DNA Damage Response (DDR) Aberrations: Preclinical and Phase 1b Results
Ezra Y Rosen, Timothy A Yap, Elisa Fontana, et al.
Page
of 10